FunPep Company Limited (4881.T)
JPY 131.0
(0.77%)
JPY 131.0
(0.77%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 313.82 Million JPY | 21.74% |
| 2022 | 257.78 Million JPY | 23.09% |
| 2021 | 209.41 Million JPY | 3.37% |
| 2020 | 202.58 Million JPY | -64.7% |
| 2019 | 573.96 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 85.12 Million JPY | 20.87% |
| 2024 Q2 | 201.55 Million JPY | 136.77% |
| 2023 Q2 | 87.45 Million JPY | 3.64% |
| 2023 Q4 | 70.42 Million JPY | -1.59% |
| 2023 Q1 | 84.37 Million JPY | -75.63% |
| 2023 FY | 313.82 Million JPY | 21.74% |
| 2023 Q3 | 71.56 Million JPY | -18.16% |
| 2022 Q3 | 295.58 Million JPY | 0.0% |
| 2022 FY | 257.78 Million JPY | 23.09% |
| 2022 Q4 | 346.3 Million JPY | 17.16% |
| 2021 FY | 209.41 Million JPY | 3.37% |
| 2020 FY | 202.58 Million JPY | -64.7% |
| 2019 FY | 573.96 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 75.568% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | 45.594% |
| GNI Group Ltd. | 9.32 Billion JPY | 96.634% |
| Linical Co., Ltd. | 2.7 Billion JPY | 88.399% |
| Trans Genic Inc. | 2.15 Billion JPY | 85.47% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 78.955% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 89.781% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 83.1% |
| AnGes, Inc. | 8.9 Billion JPY | 96.475% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | 66.724% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 98.365% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | 24.012% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | 67.825% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 87.778% |
| CanBas Co., Ltd. | 278 Million JPY | -12.885% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | 72.509% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 82.738% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 80.432% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 86.781% |
| PeptiDream Inc. | 9.68 Billion JPY | 96.76% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 83.994% |
| Ribomic Inc. | 1.1 Billion JPY | 71.618% |
| SanBio Company Limited | 4.53 Billion JPY | 93.086% |
| Healios K.K. | 3.48 Billion JPY | 91.0% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | 72.823% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 76.483% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 77.64% |
| StemRIM | 2.07 Billion JPY | 84.883% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 84.017% |
| Kringle Pharma, Inc. | 958.01 Million JPY | 67.242% |
| Stella Pharma Corporation | 963.98 Million JPY | 67.445% |
| TMS Co., Ltd. | 943.25 Million JPY | 66.73% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | 71.208% |
| Cuorips Inc. | 598.11 Million JPY | 47.532% |
| K Pharma,Inc. | 543.94 Million JPY | 42.306% |
| Takara Bio Inc. | 23.9 Billion JPY | 98.687% |
| ReproCELL Incorporated | 1.51 Billion JPY | 79.272% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | 73.495% |
| StemCell Institute Inc. | 1.16 Billion JPY | 72.996% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 79.385% |
| CellSeed Inc. | 804.93 Million JPY | 61.013% |